--- title: "Satellos Bioscience (MSCL) news: offering" url: "https://aibio.space/companies/satellos-bioscience/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MSCL offering news: Satellos Bioscience reports US$57.2 million February offering, runway through 2027. Satellos Bioscience Inc (TSX: MSCL), Canada." --- MSCL Satellos Bioscience Inc TSX · Canada # Satellos Bioscience (MSCL) news MSCL offering news Listings · 2026-08-13 ## [Satellos reports $47,251 thousand net equity proceeds in first half of 2026](https://aibio.space/news/satellos-reports-47-251-thousand-net-equity-proceeds-first-half-2026/) Cash and short-term investments stood at $7,393 thousand and $54,446 thousand at June 30, 2026. The shares were consolidated twelve-for-one in January. ## Latest Satellos Bioscience news 1. 2026-03-27 Financings [Satellos Bioscience reports US$57.2 million February offering, runway through 2027](https://aibio.space/news/satellos-bioscience-reports-us-57-2-million-february-offering-runway/) Satellos Bioscience Inc closed the equity offering on February 9, 2026 and began trading on the Nasdaq Global Market under the ticker MSLE. Cash was $27.7 million at year end. ## Satellos Bioscience at a glance - **Ticker**: MSCL - **Listing**: TSX - **Country**: Canada - **Cash, Dec 31, 2025**: $27.7 million ### Related companies - [Knight Therapeutics](https://aibio.space/companies/knight-therapeutics/) TSX: GUD - [Medicure](https://aibio.space/companies/medicure/) TSXV: MPH - [InMed Pharmaceuticals](https://aibio.space/companies/inmed-pharmaceuticals/) NASDAQ: INM - [NervGen Pharma](https://aibio.space/companies/nervgen-pharma/) NASDAQ: NGEN - [Telescope Innovations](https://aibio.space/companies/telescope-innovations/) CSE: TELI - [Waverley Pharma](https://aibio.space/companies/waverley-pharma/) TSXV: WAVE - [ABATTIS BIOCEUTICALS CORP](https://aibio.space/companies/abattis-bioceuticals/) OTC: ATTBF - [HLS Therapeutics](https://aibio.space/companies/hls-therapeutics/) TSX: HLS ### Also on TSX - [Knight Therapeutics](https://aibio.space/companies/knight-therapeutics/) GUD - [HLS Therapeutics](https://aibio.space/companies/hls-therapeutics/) HLS - [Medicenna Therapeutics](https://aibio.space/companies/medicenna-therapeutics/) MDNA - [Cipher Pharmaceuticals](https://aibio.space/companies/cipher-pharmaceuticals/) CPH - [Eupraxia Pharmaceuticals](https://aibio.space/companies/eupraxia-pharmaceuticals/) EPRX - [Medexus Pharmaceuticals](https://aibio.space/companies/medexus-pharmaceuticals/) MDP ## Satellos Bioscience annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$18.4 million](https://www.sec.gov/Archives/edgar/data/1421642/000110465926035729/) | [$14.4 million](https://www.sec.gov/Archives/edgar/data/1421642/000110465926035729/) | | Net income (loss) | [-$24.9 million](https://www.sec.gov/Archives/edgar/data/1421642/000110465926035729/) | [-$20.6 million](https://www.sec.gov/Archives/edgar/data/1421642/000110465926035729/) | | Cash from operations | [-$23.6 million](https://www.sec.gov/Archives/edgar/data/1421642/000110465926035729/) | [-$18.3 million](https://www.sec.gov/Archives/edgar/data/1421642/000110465926035729/) | | Cash and equivalents | [$9.8 million](https://www.sec.gov/Archives/edgar/data/1421642/000110465926035729/) | [$40.1 million](https://www.sec.gov/Archives/edgar/data/1421642/000110465926035729/) | | Short-term investments | [$17.9 million](https://www.sec.gov/Archives/edgar/data/1421642/000110465926035729/) | [$8.5 million](https://www.sec.gov/Archives/edgar/data/1421642/000110465926035729/) | Latest balance sheet, Dec 31, 2025 (40-F): cash and equivalents $9.8 million, plus short-term investments of $17.9 million, $27.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Satellos Bioscience Has Satellos Bioscience raised money recently? Our latest story on this, dated Mar 27, 2026: "Satellos Bioscience reports US$57.2 million February offering, runway through 2027". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/satellos-bioscience-reports-us-57-2-million-february-offering-runway/). What is the ticker symbol of Satellos Bioscience? Satellos Bioscience Inc trades under the ticker MSCL on TSX. Where is Satellos Bioscience listed? Satellos Bioscience Inc is listed on TSX. Our directory also records these other listings: LSX:A4211W; NASDAQ:MSLE; NEO:MSCL. What is the SEC CIK of Satellos Bioscience? The SEC Central Index Key (CIK) for Satellos Bioscience Inc is 1421642. Its filings are on SEC EDGAR. Which country or territory is Satellos Bioscience listed under? Our directory records Satellos Bioscience Inc under Canada. What does Satellos Bioscience do? Our directory classifies Satellos Bioscience Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Satellos Bioscience? The ISIN recorded for Satellos Bioscience Inc is CA80401L8033. Does aibio.space cover Satellos Bioscience? aibio.space lists Satellos Bioscience Inc among 2,820 public biotech companies and publishes its news here as stories appear. Where is Satellos Bioscience incorporated? SEC records list its state or country of incorporation as Z4. Is Satellos Bioscience profitable? Satellos Bioscience Inc reported a net loss of $24.9 million for the fiscal year ended Dec 31, 2025, and used $23.6 million of cash in operations, per its annual report to the SEC. How much does Satellos Bioscience spend on research and development? $18.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Satellos Bioscience have? $27.7 million in cash and short-term investments at Dec 31, 2025, per its 40-F. What is the latest Satellos Bioscience (MSCL) stock news? Our latest story on Satellos Bioscience, dated Aug 13, 2026: "Satellos reports $47,251 thousand net equity proceeds in first half of 2026". Cash and short-term investments stood at $7,393 thousand and $54,446 thousand at June 30, 2026. The shares were consolidated twelve-for-one in January. [Source](https://aibio.space/news/satellos-reports-47-251-thousand-net-equity-proceeds-first-half-2026/). How long will Satellos Bioscience's cash last? From our story of Aug 13, 2026: The capital management note says the company intends to continue as a going concern, but that its continued operations depend on generating future cash flows or obtaining additional funding. [Source](https://aibio.space/news/satellos-reports-47-251-thousand-net-equity-proceeds-first-half-2026/). Is Satellos Bioscience at risk of delisting? Our latest listing story, dated Aug 13, 2026: "Satellos reports $47,251 thousand net equity proceeds in first half of 2026". Cash and short-term investments stood at $7,393 thousand and $54,446 thousand at June 30, 2026. The shares were consolidated twelve-for-one in January. [Source](https://aibio.space/news/satellos-reports-47-251-thousand-net-equity-proceeds-first-half-2026/). ## Investor discussion: Satellos Bioscience Members talk about Satellos Bioscience (MSCL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Satellos Bioscience, newest first. Each line links the filing it comes from. 1. 2026-08-13 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1421642/000117184326005503/exh_991.htm) 2. 2026-05-15 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1421642/000117184326003453/exh_991.htm) 3. 2026-03-27 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1421642/000117184326001965/exh_991.htm) 4. 2026-02-10 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1421642/000110465926012228/tm264479d9_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open TSX:MSCL on TradingView](https://www.tradingview.com/symbols/TSX-MSCL/). ## SEC filings and registration - **SEC name**: Satellos Bioscience Inc. - **CIK**: 1421642 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: MSLE (Nasdaq) - **State or country of incorporation**: Z4 - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 15 ALLSTATE PARKWAY, MARKHAM, L3R 5B4 - **Phone**: 647-660-1780 - **Former names**: ICO THERAPEUTICS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1421642/000117184326006724/f6k_102026.htm) filed 2026-10-21 - [6-K](https://www.sec.gov/Archives/edgar/data/1421642/000117184326006380/f6k_100226.htm) filed 2026-10-05 - [6-K](https://www.sec.gov/Archives/edgar/data/1421642/000117184326006303/f6k_092926.htm) filed 2026-09-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1421642/000117184326006202/f6k_092326.htm) filed 2026-09-24 - [6-K](https://www.sec.gov/Archives/edgar/data/1421642/000117184326006046/f6k_091426.htm) filed 2026-09-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1421642/000117184326005936/f6k_090826.htm) filed 2026-09-09 - [6-K](https://www.sec.gov/Archives/edgar/data/1421642/000117184326005825/f6k_083126.htm) filed 2026-09-01 - [6-K](https://www.sec.gov/Archives/edgar/data/1421642/000110465926097247/tm2623194d1_6k.htm) filed 2026-08-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001421642), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Satellos Bioscience Inc is a public biotech or pharmaceutical company listed on TSX under the ticker MSCL, recorded under Canada. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Satellos Bioscience Inc - **Ticker**: MSCL - **Listing**: TSX - **Country or territory**: Canada - **Business scope**: Pharmaceuticals: Major - **ISIN**: CA80401L8033 - **Other listed symbols**: LSX:A4211W; NASDAQ:MSLE; NEO:MSCL - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/TSX-MSCL/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/satellos-bioscience/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Satellos Bioscience (MSCL) news: offering", 2026-10-31, https://aibio.space/companies/satellos-bioscience/